tiprankstipranks
Altimmune (MX:ALT1)
NASDAQ:ALT1
Mexico Market
ALT1
Altimmune
RESEARCH TOOLSreports

Altimmune (ALT1) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

ALT1 Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Altimmune
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALT1 Stock 12 Month Forecast

Average Price Target

$267.01
Based on 6 Wall Street analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $267.01 with a high forecast of $350.18 and a low forecast of $175.09. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"44":"$44","351":"$351","120.75":"$120.8","197.5":"$197.5","274.25":"$274.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":350.17683939999995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$350.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":267.0098400425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$267.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":175.08841969999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$175.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[44,120.75,197.5,274.25,351],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54,76.78283379999999,99.56566759999998,122.34850139999999,145.13133519999997,167.91416899999996,190.69700279999998,213.47983659999997,236.26267039999996,259.0455042,281.8283379999999,304.61117179999997,327.39400559999996,{"y":350.17683939999995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54,70.38537231096154,86.77074462192309,103.15611693288461,119.54148924384616,135.92686155480772,152.31223386576923,168.69760617673077,185.08297848769232,201.46835079865386,217.8537231096154,234.23909542057694,250.62446773153846,{"y":267.0098400425,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54,63.31449382307692,72.62898764615385,81.94348146923076,91.25797529230769,100.5724691153846,109.88696293846152,119.20145676153845,128.51595058461538,137.83044440769228,147.1449382307692,156.45943205384611,165.77392587692304,{"y":175.08841969999997,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.89,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.51,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$350.18Average Price Target$267.01Lowest Price Target$175.09
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on MX:ALT1
Thomas Smith
Leerink Partners
Leerink Partners
$175.09
Buy
―
Initiated
06/22/26
Altimmune initiated with an Outperform at LeerinkAltimmune initiated with an Outperform at Leerink
H.C. Wainwright Analyst forecast on MX:ALT1
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$350.18
Buy
―
Reiterated
06/03/26
H.C. Wainwright Sticks to Their Buy Rating for Altimmune (ALT)
Truist Financial Analyst forecast on MX:ALT1
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Citizens JMP Analyst forecast on MX:ALT1
Jonathan Wolleben
Citizens JMP
Citizens JMP
$245.12→$192.6
Buy
―
Reiterated
05/14/26
Altimmune price target lowered to $11 from $14 at CitizensAltimmune price target lowered to $11 from $14 at Citizens
Barclays Analyst forecast on MX:ALT1
Eliana Merle
Barclays
Barclays
$350.18
Buy
―
Reiterated
05/14/26
Analysts Conflicted on These Healthcare Names: Altimmune (NASDAQ: ALT), Brookdale Senior Living (NYSE: BKD) and Johnson & Johnson (NYSE: JNJ)
William Blair Analyst forecast on MX:ALT1
Andy Hsieh
William Blair
William Blair
―
Hold
―
Reiterated
05/13/26
Analysts Conflicted on These Healthcare Names: Altimmune (NASDAQ: ALT) and Acurx Pharmaceuticals (NASDAQ: ACXP)
Goldman Sachs Analyst forecast on MX:ALT1
Corinne Johnson
Goldman Sachs
Goldman Sachs
$17.51→$43.77
Hold
―
Upgraded
04/24/26
Altimmune upgraded to Neutral from Sell at Goldman SachsAltimmune upgraded to Neutral from Sell at Goldman Sachs
B. Riley Securities Analyst forecast on MX:ALT1
William Wood
B. Riley Securities
B. Riley Securities
$315.16→$227.61
Buy
―
Reiterated
03/06/26
Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Altimmune (NASDAQ: ALT) and Cormedix (NASDAQ: CRMD)
JonesTrading Analyst forecast on MX:ALT1
Boris Peaker
JonesTrading
JonesTrading
$122.56
Buy
―
Initiated
02/13/26
Altimmune initiated with a Buy at Titan PartnersAltimmune initiated with a Buy at Titan Partners
Stifel Nicolaus Analyst forecast on MX:ALT1
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
―
Buy
―
Reiterated
12/19/25
Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)
Evercore ISI Analyst forecast on MX:ALT1
Michael DiFiore
Evercore ISI
Evercore ISI
$437.72
Buy
―
Initiated
08/22/25
Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on MX:ALT1
Thomas Smith
Leerink Partners
Leerink Partners
$175.09
Buy
―
Initiated
06/22/26
Altimmune initiated with an Outperform at LeerinkAltimmune initiated with an Outperform at Leerink
H.C. Wainwright Analyst forecast on MX:ALT1
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$350.18
Buy
―
Reiterated
06/03/26
H.C. Wainwright Sticks to Their Buy Rating for Altimmune (ALT)
Truist Financial Analyst forecast on MX:ALT1
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Citizens JMP Analyst forecast on MX:ALT1
Jonathan Wolleben
Citizens JMP
Citizens JMP
$245.12→$192.6
Buy
―
Reiterated
05/14/26
Altimmune price target lowered to $11 from $14 at CitizensAltimmune price target lowered to $11 from $14 at Citizens
Barclays Analyst forecast on MX:ALT1
Eliana Merle
Barclays
Barclays
$350.18
Buy
―
Reiterated
05/14/26
Analysts Conflicted on These Healthcare Names: Altimmune (NASDAQ: ALT), Brookdale Senior Living (NYSE: BKD) and Johnson & Johnson (NYSE: JNJ)
William Blair Analyst forecast on MX:ALT1
Andy Hsieh
William Blair
William Blair
―
Hold
―
Reiterated
05/13/26
Analysts Conflicted on These Healthcare Names: Altimmune (NASDAQ: ALT) and Acurx Pharmaceuticals (NASDAQ: ACXP)
Goldman Sachs Analyst forecast on MX:ALT1
Corinne Johnson
Goldman Sachs
Goldman Sachs
$17.51→$43.77
Hold
―
Upgraded
04/24/26
Altimmune upgraded to Neutral from Sell at Goldman SachsAltimmune upgraded to Neutral from Sell at Goldman Sachs
B. Riley Securities Analyst forecast on MX:ALT1
William Wood
B. Riley Securities
B. Riley Securities
$315.16→$227.61
Buy
―
Reiterated
03/06/26
Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Altimmune (NASDAQ: ALT) and Cormedix (NASDAQ: CRMD)
JonesTrading Analyst forecast on MX:ALT1
Boris Peaker
JonesTrading
JonesTrading
$122.56
Buy
―
Initiated
02/13/26
Altimmune initiated with a Buy at Titan PartnersAltimmune initiated with a Buy at Titan Partners
Stifel Nicolaus Analyst forecast on MX:ALT1
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
―
Buy
―
Reiterated
12/19/25
Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)
Evercore ISI Analyst forecast on MX:ALT1
Michael DiFiore
Evercore ISI
Evercore ISI
$437.72
Buy
―
Initiated
08/22/25
Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
GKOSGlaukos
ARDXArdelyx
STOKStoke Therapeutics
MIRMMirum Pharmaceuticals
CSTLCastle Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Altimmune

3 Months
Jonathan WollebenCitizens JMP
Success Rate
13/33 ratings generated profit
39%
Average Return
+27.25%
Copying Jonathan Wolleben's trades and holding each position for 3 Months would result in 39.39% of your transactions generating a profit, with an average return of +27.25% per trade.
1 Year
Jonathan WollebenCitizens JMP
Success Rate
10/33 ratings generated profit
30%
Average Return
+5.22%
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 30.30% of your transactions generating a profit, with an average return of +5.22% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
11/33 ratings generated profit
33%
Average Return
-21.65%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -21.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALT1 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
8
5
8
6
6
Buy
0
0
2
2
2
Hold
1
2
3
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
7
13
10
9
In the current month, ALT1 has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ALT1 average Analyst price target in the past 3 months is 267.01.
Each month's total comprises the sum of three months' worth of ratings.

ALT1 Financial Forecast

ALT1 Earnings Forecast

Next quarter’s earnings estimate for ALT1 is -$2.45 with a range of -$3.68 to -$1.75. The previous quarter’s EPS was -$3.15. ALT1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ALT1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for ALT1 is -$2.45 with a range of -$3.68 to -$1.75. The previous quarter’s EPS was -$3.15. ALT1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ALT1 has Performed in-line its overall industry.

ALT1 Sales Forecast

Next quarter’s sales forecast for ALT1 is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ALT1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ALT1 has Performed in-line its overall industry.
Next quarter’s sales forecast for ALT1 is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ALT1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ALT1 has Performed in-line its overall industry.

ALT1 Stock Forecast FAQ

What is MX:ALT1’s average 12-month price target, according to analysts?
Based on analyst ratings, Altimmune’s 12-month average price target is 267.01.
    What is MX:ALT1’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:ALT1, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Altimmune a Buy, Sell or Hold?
        Altimmune has a consensus rating of Strong Buy, which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Altimmune’s share price target?
          The average share price target for Altimmune is 267.01. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $350.18 ,and the lowest forecast is $175.09. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Altimmune?
            Altimmune’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
              How can I buy shares of Altimmune?
              To buy shares of MX:ALT1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.